High dose inhaled nitric oxide resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease.
Patients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Sildenafil given with with ambrisentan, and not bosentan, may be better suited for patients with pulmonary arterial hypertension.
In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read More
Treatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read More
Development of pulmonary arterial hypertension (PAH) may be related to increased production of Nestin protein in the pulmonary vasculature, a Plos One study reports.
Read More
Research reports that male sex may be predictive of right ventricular dysfunction in some pulmonary hypertension patients.
Read More
RTs may find it difficult to choose between available inhaled pulmonary vasodilators (IPVs)—inhaled nitric oxide or nebulized epoprostenol—to treat pulmonary hypertension.
Read More
Preterm infants born younger than 29 weeks’ gestational age who were treated for pulmonary...
Read More
The American Lung Association will host a Lung Force Expo on June 15 in Kansas City, Mo.
Read More
Adenotonsillectomy resulted in significant improvements in blood pressure for children suffering with obstructive sleep apnea (OSA) and hypertension.
Read More
Temple University Hospital performed 131 lung transplants in 2017, making it the highest-volume...
Read More
The Y chromosome provides protection against pulmonary hypertension and may be the reason the disease is less prevalent among men than women.
Read More
Patients with sarcoidosis frequently develop pulmonary hypertension, which is associated with an 8- to 10-fold increase in mortality among sarcoidosis patients.
Read More
According to new research from Cleveland Clinic, the use of carvedilol, a beta blocker, had a positive effect on treatment of pulmonary arterial hypertension.
Read More